Horm Metab Res 2007; 39(8): 596-600
DOI: 10.1055/s-2007-984459
Clinical Human

© Georg Thieme Verlag KG Stuttgart · New York

Immune-mediated Activation of the Endocannabinoid System in Visceral Adipose Tissue in Obesity

K. Kempf 1 , J. Hector 2 , T. Strate 3 , B. Schwarzloh 2 , B. Rose 1 , C. Herder 1 , S. Martin 1 , P. Algenstaedt 2
  • 1Institute for Clinical Diabetes Research, German Diabetes Center, Leibniz Institute at Heinrich Heine University Düsseldorf, Düsseldorf, Germany
  • 2Department of Internal Medicine, University Hamburg-Eppendorf, Hamburg, Germany
  • 3Department of Surgery, University Hamburg-Eppendorf, Hamburg, Germany
Further Information

Publication History

received 15.12.2006

accepted 21.05.2007

Publication Date:
21 August 2007 (online)

Abstract

The aim of the study was to investigate if the endocannabinoid system (ECS) is activated in visceral adipose tissue and if adipose tissue inflammation affects the ECS activation state. Therefore, expression of fatty acid amide hydrolase (FAAH), cannabinoid receptor 1 (Cb1), adiponectin, and tumor necrosis factor (TNF)-α was compared in visceral adipose tissue from 10 normal-weight (BMI 24.4±1.1 kg/m2) and 11 obese subjects (BMI 37.6±13.6 kg/m2) using quantitative RT-PCR, and gene expression changes were analyzed after in vitro stimulation of visceral adipose tissue with TNF-α. The data demonstrate that the ECS is activated in obese visceral adipose tissue as shown by decreased FAAH, Cb1, and adiponectin expression. Obesity-related ECS activation is accompanied by elevated expression of the pro-inflammatory cytokine TNF-α, which in turn stimulates ECS activation in vitro. Our data show a strong association between adipose tissue inflammation and ECS activation in obesity, and indicate that a pro-inflammatory state may directly activate the ECS.

References

  • 1 Di MV, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake.  Nature. 2001;  410 822-825
  • 2 Gonzalez S, Manzanares J, Berrendero F, Wenger T, Corchero J, Bisogno T, Romero J, Fuentes JA, Di MV, Ramos JA, Fernandez-Ruiz J. Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland.  Neuroendocrinology. 1999;  70 137-145
  • 3 Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.  Pharmacol Rev. 2002;  54 161-202
  • 4 Osei-Hyiaman D, Petrillo M De, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.  J Clin Invest. 2005;  115 1298-1305
  • 5 Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.  Mol Pharmacol. 2003;  63 908-914
  • 6 Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, Baron JF, Haffaf Y, Cesari M, Festy F. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes.  Histochem Cell Biol. 2006;  1-11
  • 7 Gaal LF Van, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.  Lancet. 2005;  365 1389-1397
  • 8 Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.  N Engl J Med. 2005;  353 2121-2134
  • 9 Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.  JAMA. 2006;  295 761-775
  • 10 Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM, Jordan J. Activation of the peripheral endocannabinoid system in human obesity.  Diabetes. 2005;  54 2838-2843
  • 11 Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.  J Clin Invest. 2003;  112 1821-1830
  • 12 Weisberg SP, MacCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW. Obesity is associated with macrophage accumulation in adipose tissue.  J Clin Invest. 2003;  112 1796-1808
  • 13 Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D, Coussieu C, Basdevant A, Hen AB, Bedossa P, Guerre-Millo M, Clement K. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity.  Diabetes. 2006;  55 1554-1561
  • 14 Fernandez-Solari J, Prestifilippo JP, Bornstein SR, MacCann SM, Rettori V. Participation of the endocannabinoid system in the effect of TNF-alpha on hypothalamic release of gonadotropin-releasing hormone.  Ann N Y Acad Sci. 2006;  1088 238-250
  • 15 Hector J, Schwarzloh B, Goehring J, Strate TG, Hess UF, Deuretzbacher G, Hansen-Algenstaedt N, Beil FU, Algenstaedt P. TNF-alpha Alters Visfatin and Adiponectin Levels in Human Fat.  Horm Metab Res. 2007;  39 250-255
  • 16 Kempf K, Haltern G, Futh R, Herder C, Muller-Scholze S, Gulker H, Martin S. Increased TNF-alpha and decreased TGF-beta expression in peripheral blood leukocytes after acute myocardial infarction.  Horm Metab Res. 2006;  38 346-351
  • 17 Kempf K, Rose B, Herder C, Haastert B, Fusbahn-Laufenburg A, Reifferscheid A, Scherbaum WA, Kolb H, Martin S. The metabolic syndrome sensitizes leukocytes for glucose-induced immune gene expression.  J Mol Med. 2007;  85 389-396
  • 18 Di MV, Bisogno T, Petrocellis L De, Melck D, Orlando P, Wagner JA, Kunos G. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages.  Eur J Biochem. 1999;  264 258-267
  • 19 Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, Pacher P, Schon MR, Jordan J, Stumvoll M. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity.  Diabetes. 2006;  55 3053-3060
  • 20 Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity.  J Biol Chem. 1996;  271 10697-10703
  • 21 Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.  Biochem Biophys Res Commun. 1999;  257 79-83
  • 22 Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.  J Clin Endocrinol Metab. 2001;  86 1930-1935
  • 23 Curat CA, Miranville A, Sengenes C, Diehl M, Tonus C, Busse R, Bouloumie A. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes.  Diabetes. 2004;  53 1285-1292
  • 24 Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion.  J Clin Endocrinol Metab. 2007;  92 1023-1033
  • 25 Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.  Diabetes. 2001;  50 2094-2099
  • 26 Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, Shohami E. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines.  Neurobiol Dis. 2006;  22 257-264
  • 27 Verhoeckx KC, Korthout HA, Meeteren-Kreikamp AP, Ehlert KA, Wang M, van der GJ, Rodenburg RJ, Witkamp RF. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways.  Int Immunopharmacol. 2006;  6 656-665
  • 28 Germain N, Boichot E, Advenier C, Berdyshev EV, Lagente V. Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-alpha production by human mononuclear cells.  Int Immunopharmacol. 2002;  2 537-543
  • 29 Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, Peterson PK. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes.  Glia. 2005;  49 211-219
  • 30 Ramirez BG, Blazquez C, Gomez DP, Guzman M, Ceballos ML de. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.  J Neurosci. 2005;  25 1904-1913
  • 31 Fernandez-Lopez D, Martinez-Org, Nunez E, Romero J, Lorenzo P, Moro MA, Lizasoain I. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats.  Pediatr Res. 2006;  60 169-173
  • 32 Ortega-Gutierrez S, Molina-Holgado E, Arevalo-Martin A, Correa F, Viso A, Lopez-Rodriguez ML, Di MV, Guaza C. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis.  FASEB J. 2005;  19 1338-1340
  • 33 Daaka Y, Zhu W, Friedman H, Klein TW. Induction of interleukin-2 receptor alpha gene by delta9-tetrahydrocannabinol is mediated by nuclear factor kappaB and CB1 cannabinoid receptor.  DNA Cell Biol. 1997;  16 301-309
  • 34 Smith SR, Terminelli C, Denhardt G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice.  J Pharmacol Exp Ther. 2000;  293 136-150
  • 35 Croci T, Landi M, Galzin AM, Marini P. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents.  Br J Pharmacol. 2003;  140 115-122
  • 36 Costa B, Trovato AE, Colleoni M, Giagnoni G, Zarini E, Croci T. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve.  Pain. 2005;  116 52-61
  • 37 Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.  J Clin Invest. 2003;  112 423-431

Correspondence

Dr. K. Kempf

Institute for Clinical Diabetes Research

German Diabetes Center

Leibniz Institute at Heinrich Heine University Düsseldorf

Auf'm Hennekamp 65

40225 Düsseldorf

Germany

Phone: +49/211/3382 64 7

Fax: +49/211/3382 60 3

Email: Kerstin.Kempf@ddz.uni-duesseldorf.de